Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer


Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2007.0063

COMMENTAR?

 

Gene signatures and breast cancer network biology: Ready to the clinic?
Ioannis Sainis, Ph.D. and Dimitrios H. Roukos, MD
 

Since there is no abstract we provide the first sentence
Despite the robustness of standard clinicopathologic features (tumor size and grade, nodal status, and ER/HER2 status) in clinical practice, they are inappropriate for tailoring the best treatment to individual patients with early-stage breast cancer. Even for the latest great clinical success of translational research with anti-HER2 drugs only approximately 10% of breast cancer patientsí benefits: HER2-positive disease accounts for 25% of all given and among these patients the clinical response does not exceed 40%. It is clear. Biomarkers are therefore urgently needed. Personalized treatment represents the highest priority in cancer research [1]. Could the 76-gene signature [2] be used as a molecular diagnostic tool to the clinic for sparing adjuvant chemotherapy toxicity?

 

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 3 February 2004